LY3537982 Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since May 2026

Also known as: Olomorasib

Pipeline

Phase 3: 1

Top Sponsors

Eli Lilly and Company1

Indications

Neoplasm Metastasis1
Carcinoma, Non-Small-Cell Lung1
Lung Cancer1
Cancer1

Huntsville, Alabama1 trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Clearview Cancer Institute

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.